or Try an Advanced Search...

    Technical Analysis for OCGN - Ocugen, Inc.

    Grade Last Price % Change Price Change
    B 2.00 1.97% 0.04
    OCGN closed up 15.29 percent on Wednesday, May 15, 2024, on 1.6 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Up
    Historical OCGN trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing High Bullish 1.97%
    Pocket Pivot Bullish Swing Setup 1.97%
    Upper Bollinger Band Walk Strength 1.97%
    Wide Bands Range Expansion 1.97%
    Above Upper BB Strength 1.97%
    Overbought Stochastic Strength 1.97%
    Upper Bollinger Band Touch Strength 1.97%
    New Uptrend Bullish 17.57%
    Inside Day Range Contraction 17.57%
    Wide Bands Range Expansion 17.57%
    Older End-of-Day Signals for OCGN ...

       Recent Intraday Alerts

    Alert Time
    Up 5% about 5 hours ago
    Rose Above Previous Day's High about 5 hours ago
    2x Volume Pace about 5 hours ago
    1.5x Volume Pace about 5 hours ago
    Up 3% about 5 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    OCGN Chart by TradingView
    Basic chart:

    Profile

    Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company based in Malvern, Pennsylvania.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Organ Systems Eye Ophthalmology Vision Diabetic Retinopathy Eye Diseases Retina Blindness Retinopathy Host Disease Innovative Therapies Retinitis Graft Versus Host Disease Retinitis Pigmentosa

    Is OCGN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 16 Nayax Posts Weak Q1 Results, Joins GameStop, Iris Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
    May 15 Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
    May 15 Ocugen Inc (OCGN) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances Amid ...
    May 15 Q1 2024 Ocugen Inc Earnings Call
    May 14 Ocugen, Inc. (OCGN) Q1 2024 Earnings Call Transcript
    May 14 Ocugen GAAP EPS of -$0.05 beats by $0.01, revenue of $1.01M
    May 14 Ocugen Provides Business Update with First Quarter 2024 Financial Results
    May 13 Ocugen Q1 2024 Earnings Preview
    May 10 Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
    May 10 Ocugen to Present at May 2024 Investor Conferences
    See more OCGN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.105
    52 Week Low 0.345
    Average Volume 9,743,540
    200-Day Moving Average 0.73
    50-Day Moving Average 1.43
    20-Day Moving Average 1.46
    10-Day Moving Average 1.63
    Average True Range 0.19
    RSI (14) 65.03
    ADX 26.85
    +DI 29.77
    -DI 10.81
    Chandelier Exit (Long, 3 ATRs) 1.44
    Chandelier Exit (Short, 3 ATRs) 1.67
    Upper Bollinger Bands 1.90
    Lower Bollinger Band 1.01
    Percent B (%b) 1.06
    BandWidth 60.91
    MACD Line 0.11
    MACD Signal Line 0.06
    MACD Histogram 0.0481
    Fundamentals Value
    Market Cap 502.74 Million
    Num Shares 257 Million
    EPS -0.32
    Price-to-Earnings (P/E) Ratio -6.13
    Price-to-Sales 25069.32
    Price-to-Book 2.36
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.43
    Resistance 3 (R3) 2.39 2.19 2.35
    Resistance 2 (R2) 2.19 2.07 2.21 2.32
    Resistance 1 (R1) 2.08 2.00 2.14 2.12 2.30
    Pivot Point 1.88 1.88 1.91 1.90 1.88
    Support 1 (S1) 1.77 1.76 1.83 1.81 1.62
    Support 2 (S2) 1.57 1.69 1.59 1.60
    Support 3 (S3) 1.46 1.57 1.57
    Support 4 (S4) 1.50